Clinical Trial Update: Tolerability and Effectiveness of CGB-500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic Dermatitis [Phase 1, Phase 2]

View source ↗

Summary

The document reports on completed Phase 1/2 studies assessing tolerability and effectiveness of CGB-500 topical ointment containing 1% tofacitinib for Atopic De…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• CGB-500 Topical Ointment (1% tofacitinib) (tofacitinib)

Snippet

Sponsor: CAGE Bio Inc. | Conditions: Atopic Dermatitis | Phase 1, Phase 2 | Status: COMPLETED